NEW YORK, July 22 - Lynx Therapeutics has signed up Innovative Dairy Products of Australia as a gene expression services customer, the company said today.
Under the agreement, Lynx, of Hayward, Calif., will use its Massively Parallel Signature Sequencing technology to study gene expression in mammary tissue of the Australian wallaby, the fur seal, and the dairy cow, and will be paid for the services.
"We believe that this study will provide invaluable data on key genes involved in lactation performance," Thomas Vasicek, vice president of business development at Lynx, said in a statement.
Innovative Dairy products is acting as an agent for the Cooperative Research Center for Innovative Dairy Products of Australia, an R&D consortium formed by commercial and research aspects of the Australian dairy industry to develop and commercialize genomic and reproductive technologies for the industry, the organization said.
In 2003, Lynx has signed agreements to use its MPSS technology with the Genome Institute of Singapore in transcriptome studies; Northeastern University to study the Antarctic icefish; the National Institutes on Aging; Millennium Pharmaceuticals; the Livestock Research Institute in Nairobi, Kenya; the Center for Tropical Veterinary Medicine in Edinburgh, Scotland; and the Institute for Systems Biology and IBM.